Clinical trials: Hypnotic; Sleep Disorder
- Condition Hypnotic; Sleep Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Healthy Subjects, Sleep Initiation and Maintenance Disorders
An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.
- Trial name
- NCT00699608
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Short-term Insomnia
Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia
The purpose of this study is to evaluate the effect of a combination drug product containing diphenhydramine, zolpidem and lorazepam on total sleep time.
- Trial name
- NCT02671760
- Testing
- SM-1, Comparator
- Volunteers
- 39 people
- Sponsor
- Sequential Medicine Ltd
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Insomnia, Attention Deficit Hyperactivity Disorder
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention…
- Trial name
- NCT00856973
- Testing
- eszopiclone
- Where
- 73 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
Sleep Disorder, Primary Insomnia
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
SKP-1041 is a new formulation of a marketed sleeping agent called zaleplon. Zaleplon is currently available as Sonata as well as several generic formulations. Sonata and its generics induce sleep soon after ingestion.
- Trial name
- NCT00878553
- Testing
- SKP-1041 (experimental formulation of zaleplon)
- Volunteers
- 67 people
- Sponsor
- Somnus Therapeutics, Inc.